Alivus Life Sciences Limited (ALIVUS) Q1 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

Alivus Life Sciences Limited enters the Q1 FY27 results window balancing a structural margin expansion against the inherent volatility of its Glenmark Pharmaceuticals (GPL) business. Investors will be focused on whether the firm can sustain its elevated EBITDA margins above 30% while navigating the commissioning timeline of the critical Solapur facility.

Alivus Life Sciences Limited Q1 Results Date and Time

The company scheduled a board meeting for July 30, 2026, to consider and approve the Q1 FY27 unaudited financial results.

The Q1 FY27 earnings call is scheduled for July 31, 2026, from 8:30-9:30 AM IST, with universal dial-in and international toll-free numbers provided.

What to expect from Alivus Life Sciences Limited's Q1 FY27 results

Alivus Life Sciences enters the quarter with a strong base, following an FY26 performance where EBITDA margins expanded 360 bps YoY to 33.6%. While the Q4 FY26 exit margin of 34.4% provides a high benchmark, management has maintained an open-ended guidance of sustaining margins above 30% for FY27. The company faces a mixed macro environment, where a ~4% QoQ rupee depreciation acts as a tailwind for export realizations, offset by potential margin compression if the GPL business mix reverts from its Q4 high of 35.4%. Furthermore, the company continues to manage elevated working capital levels, which stood at 199 days at the end of FY26, with no immediate trigger for sharp normalization in the current quarter. The upcoming call will likely focus on whether the CDMO business has maintained its guided run-rate of Rs. 50 Cr per quarter and the operational readiness of the Solapur facility.

Key Things To Watch

Performance vs Guidance Tracking: Tracking progress against key FY27 strategic targets.

• Revenue growth — High single-digit target for FY27
• EBITDA margin — Sustained above 30% target for FY27
• CDMO run-rate — Rs. 50 Cr per quarter target from H2 FY26 onward
• Solapur commissioning — Targeted for Q2 FY27

Solapur Facility Commissioning: Updates on the major greenfield expansion project.

• Status of commissioning for the 465 KL Phase 1 capacity
• Timeline for backward integration and initial revenue contribution expectations

Operating Metric Trajectory: Monitoring key business segment performance.

• GPL business revenue — Assessing sustainability of Q4 FY26 levels of Rs. 2,439 Mn
• CDMO revenue — Tracking performance against the Rs. 50 Cr quarterly run-rate goal
• Working capital — Monitoring the 199-day cycle and receivables position

Risks and Headwinds to Monitor: Management-flagged operational and market risks.

• Price erosion — Tracking the ~4.5% overall portfolio erosion against guidance assumptions
• Cost inflation — Monitoring employee and other expenses which grew 17.1% and 23.4% YoY respectively in FY26
• Geopolitical impact — Assessing any material tariff or supply chain volatility